Partnering
Genextra's strategy values program-oriented partnerships as a necessary step for full clinical development of its programmes up to product commercialization.
Available partnering programs. We therefore encourage contacts and discussions with companies potentially interested in partnering with our subsidiaries at various stages of their clinical and pre-clinical product development.
In particular at this time, we are most interested in:
To discuss any form of potential collaboration opportunity with Genextra, please contact Dr. Federica Draghi
or find us at one of the upcoming business conference:
Tel: +39 02 36515117
Available partnering programs. We therefore encourage contacts and discussions with companies potentially interested in partnering with our subsidiaries at various stages of their clinical and pre-clinical product development.
In particular at this time, we are most interested in:
- seeking out-licensing opportunities for DAC60, a phase I/IIa topical histone deacetylase inhibitor developed for basal cell carcinoma;
- Initiating discussions with a partner interested in our HSP90 and HDAC programs;
- establishing partnering opportunities based on Congenia's mPTP mitochondrial platform.
- Establishing partnering opportunities for Tethis' cancer diagnostics application.
To discuss any form of potential collaboration opportunity with Genextra, please contact Dr. Federica Draghi
or find us at one of the upcoming business conference:
Tel: +39 02 36515117